Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18619385 | 0.89 | CA14 (0.40) | CA14CA12CA1CA7CA2 | |
| SCHEMBL25124098 | 0.87 | CA14 (0.39) | CA14CA12CA1CA7CA2 | |
| SCHEMBL24329847 | 0.87 | CA14 (0.39) | CA14CA12CA1CA7CA2 | |
| SCHEMBL18400312 | 0.86 | CA14 (0.36) | CA14CA12CA1CA7CA2 | |
| SCHEMBL13452140 | 0.85 | CA14 (0.38) | CA14CA12CA1CA7CA2 | |
| SCHEMBL12776500 | 0.85 | CA14 (0.38) | CA14CA12CA1CA7CA2 | |
| SCHEMBL12808019 | 0.85 | CA14 (0.38) | CA14CA12CA1CA7CA2 | |
| SCHEMBL25185999 | 0.85 | CA14 (0.38) | CA14CA12CA1CA7CA2 | |
| SCHEMBL16085369 | 0.85 | CA14 (0.38) | CA14CA12CA1CA7CA2 | |
| SCHEMBL1067066 | 0.84 | CA14 (0.38) | CA14CA12CA1CA7CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4046995-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2023-09-07 | — | — | US | disclosed |
| WO-2023055920-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-11564989-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4086249-A2 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | Trevena, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-2175933-B1 | TRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| EP-2183221-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | Crystax Pharmaceuticals S.L. (ES) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009007399-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277676-A1 | CAMPTOTHECINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | DCTD, ADCY8, ADCY3 | CA14 208/4885CA12 261/4885CA1 1135/4885 |
| US-11564989-B2 | Camptothecine antibody-drug conjugates and methods of use thereof | DCTD, ADCY8, ADCY3 | CA14 208/4885CA12 261/4885CA1 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.